컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

American College of Cardiology 75th Annual Scientific Session & Expo (ACC.26)

28 March - 30 March, 2026, United States

Statin-ezetimibe holds slight advantage over PCSK9is in ACS

2026-05-06

In a systematic review and network meta-analysis (NMA), a statin-ezetimibe combination yields a more favourable LDL-C reduction and a positive trend in atherosclerotic plaque regression compared with PCSK9 inhibitors (PCSK9is) alone in individuals with acute coronary syndrome (ACS).
SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

2026-05-06

Treatment with tirzepatide, a dual GLP-1* and GIP** agonist, significantly improves cardiovascular and renal outcomes in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial presented at ACC.26.
Transcatheter ViV may be a safe short-term option to repeat MVR

2026-05-06

The transcatheter valve-in-valve (ViV) procedure appears to be a safe option for select patients requiring repeat surgery after failed mitral bioprostheses, according to findings from the randomized controlled SURViV trial presented at ACC.26. However, it is still early days for the ViV approach.
Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

2026-05-06

In the treatment of patients with acute, intermediate-risk pulmonary embolism (PE), administering ultrasound-facilitated, catheter-directed thrombolysis (USCDT) on top of anticoagulation results in better short-term outcomes compared with anticoagulation alone, as shown in the multinational, adaptive-design, open-label HI-PEITHO trial.
SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

2026-05-06

Stopping beta-blockers after a year of regular use does not appear to increase the risk of adverse clinical outcomes in myocardial infarction (MI) survivors without evidence of left ventricular systolic dysfunction or heart failure (HF), as shown in the SMART-DECISION trial.
Mavacamten reduces blood flow obstruction in adolescents with HCM

2026-05-06

Treatment with mavacamten, compared with placebo, results in significantly greater reduction in left ventricular outflow tract (LVOT) obstruction over 28 weeks among adolescent patients with obstructive hypertrophic cardiomyopathy (HCM), as shown in the SCOUT-HCM trial.
More aggressive LDL-C reduction improves cardiac outcomes in ASCVD patients

2026-05-06

An intensive targeting of low-density lipoprotein cholesterol (LDL-C) level (<55 mg/dL) reduces the risk of cardiovascular events at 3 years in patients with atherosclerotic cardiovascular disease (ASCVD) when compared with conventional targeting (<70 mg/dL), results of the Ez-PAVE trial have shown.
Clopidogrel vs aspirin maintenance post-PCI with DES: Which reigns better?

2026-05-06

Results from the 10-year follow-up of the HOST-EXAM* trial favour clopidogrel over aspirin as chronic maintenance therapy after percutaneous coronary intervention (PCI) with a drug-eluting stent (DES).
Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patien

2026-05-06

In the prespecified subgroup analysis of the VESALIUS-CV trial, evolocumab significantly reduced the risk of first major adverse cardiovascular (CV) events (MACE) in individuals without known significant atherosclerosis and with diabetes.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 배석봉 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 소힐 고즈와미
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : [email protected]
무통장 입금 : 하나은행 147-910007-18204 (예금주 : 주식회사 킴스) 유료정보 가격확인

Copyright © 1987-2026 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북